Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents

Agilent Technologies Inc., announced the company intends to appeal the U.S. Patent and Trademarks Office Patent Trial and Appeal Board’s Final Written Decision in connection with the Inter Partes review of U.S. Patent Nos. 10,337,001 & 10,900,034.

Scroll to Top